Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life

Carlo Lombardi, Diego Bagnasco, Cristiano Caruso, Mariella D'Amato, Francesco Menzella, Manlio Milanese, Gianenrico Senna, Giorgio Walter Canonica, Giovanni Passalacqua

Research output: Contribution to journalArticle

Abstract

Mepolizumab (anti IL-5, monoclonal antibody) is commercially available in Italy since more than one year for the treatment of severe hypereosinophilic asthma. Its efficacy and safety were evaluated in several regulatory trials. The characteristics of this drug in real life began to be assessed only recently. We describe herein the drop-out rate observed with mepolizumab in real life, because this datum can indirectly reflect the safety and tolerability aspects. The demographic and clinical data of patients receiving mepolizumab for severe asthma were collected, and the number and reasons for discontinuation of the treatment were analyzed. The database involves 143 patients (67 male, age range 19–80 year) who received at least one dose of mepolizumab. The observed discontinuation rate was 6/143 (4.2%). Five out of 6 discontinuations were due to lack of response, and one was an adverse event (urticaria) probably related to the treatment. There was no clinical difference between the drop-out group and the patients still ongoing. As compared to the clinical trials published the discontinuation rate was lower in our population, especially for adverse events (7% vs 23.7%). Thus, the tolerability of mepolizumab, as derived from discontinuations, seems to be better in real-life than in clinical trials.

LanguageEnglish
Pages87-89
Number of pages3
JournalPulmonary Pharmacology and Therapeutics
Volume54
DOIs
Publication statusPublished - Feb 1 2019

Keywords

  • Mepolizumab
  • Real-life: dropout
  • Safety
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Lombardi, C., Bagnasco, D., Caruso, C., D'Amato, M., Menzella, F., Milanese, M., ... Passalacqua, G. (2019). Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology and Therapeutics, 54, 87-89. https://doi.org/10.1016/j.pupt.2018.12.003

Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. / Lombardi, Carlo; Bagnasco, Diego; Caruso, Cristiano; D'Amato, Mariella; Menzella, Francesco; Milanese, Manlio; Senna, Gianenrico; Canonica, Giorgio Walter; Passalacqua, Giovanni.

In: Pulmonary Pharmacology and Therapeutics, Vol. 54, 01.02.2019, p. 87-89.

Research output: Contribution to journalArticle

Lombardi, C, Bagnasco, D, Caruso, C, D'Amato, M, Menzella, F, Milanese, M, Senna, G, Canonica, GW & Passalacqua, G 2019, 'Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life', Pulmonary Pharmacology and Therapeutics, vol. 54, pp. 87-89. https://doi.org/10.1016/j.pupt.2018.12.003
Lombardi, Carlo ; Bagnasco, Diego ; Caruso, Cristiano ; D'Amato, Mariella ; Menzella, Francesco ; Milanese, Manlio ; Senna, Gianenrico ; Canonica, Giorgio Walter ; Passalacqua, Giovanni. / Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. In: Pulmonary Pharmacology and Therapeutics. 2019 ; Vol. 54. pp. 87-89.
@article{310a15e4fd8b4051a43cb87e5a4f15d8,
title = "Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life",
abstract = "Mepolizumab (anti IL-5, monoclonal antibody) is commercially available in Italy since more than one year for the treatment of severe hypereosinophilic asthma. Its efficacy and safety were evaluated in several regulatory trials. The characteristics of this drug in real life began to be assessed only recently. We describe herein the drop-out rate observed with mepolizumab in real life, because this datum can indirectly reflect the safety and tolerability aspects. The demographic and clinical data of patients receiving mepolizumab for severe asthma were collected, and the number and reasons for discontinuation of the treatment were analyzed. The database involves 143 patients (67 male, age range 19–80 year) who received at least one dose of mepolizumab. The observed discontinuation rate was 6/143 (4.2{\%}). Five out of 6 discontinuations were due to lack of response, and one was an adverse event (urticaria) probably related to the treatment. There was no clinical difference between the drop-out group and the patients still ongoing. As compared to the clinical trials published the discontinuation rate was lower in our population, especially for adverse events (7{\%} vs 23.7{\%}). Thus, the tolerability of mepolizumab, as derived from discontinuations, seems to be better in real-life than in clinical trials.",
keywords = "Mepolizumab, Real-life: dropout, Safety, Severe asthma",
author = "Carlo Lombardi and Diego Bagnasco and Cristiano Caruso and Mariella D'Amato and Francesco Menzella and Manlio Milanese and Gianenrico Senna and Canonica, {Giorgio Walter} and Giovanni Passalacqua",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.pupt.2018.12.003",
language = "English",
volume = "54",
pages = "87--89",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",

}

TY - JOUR

T1 - Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life

AU - Lombardi, Carlo

AU - Bagnasco, Diego

AU - Caruso, Cristiano

AU - D'Amato, Mariella

AU - Menzella, Francesco

AU - Milanese, Manlio

AU - Senna, Gianenrico

AU - Canonica, Giorgio Walter

AU - Passalacqua, Giovanni

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Mepolizumab (anti IL-5, monoclonal antibody) is commercially available in Italy since more than one year for the treatment of severe hypereosinophilic asthma. Its efficacy and safety were evaluated in several regulatory trials. The characteristics of this drug in real life began to be assessed only recently. We describe herein the drop-out rate observed with mepolizumab in real life, because this datum can indirectly reflect the safety and tolerability aspects. The demographic and clinical data of patients receiving mepolizumab for severe asthma were collected, and the number and reasons for discontinuation of the treatment were analyzed. The database involves 143 patients (67 male, age range 19–80 year) who received at least one dose of mepolizumab. The observed discontinuation rate was 6/143 (4.2%). Five out of 6 discontinuations were due to lack of response, and one was an adverse event (urticaria) probably related to the treatment. There was no clinical difference between the drop-out group and the patients still ongoing. As compared to the clinical trials published the discontinuation rate was lower in our population, especially for adverse events (7% vs 23.7%). Thus, the tolerability of mepolizumab, as derived from discontinuations, seems to be better in real-life than in clinical trials.

AB - Mepolizumab (anti IL-5, monoclonal antibody) is commercially available in Italy since more than one year for the treatment of severe hypereosinophilic asthma. Its efficacy and safety were evaluated in several regulatory trials. The characteristics of this drug in real life began to be assessed only recently. We describe herein the drop-out rate observed with mepolizumab in real life, because this datum can indirectly reflect the safety and tolerability aspects. The demographic and clinical data of patients receiving mepolizumab for severe asthma were collected, and the number and reasons for discontinuation of the treatment were analyzed. The database involves 143 patients (67 male, age range 19–80 year) who received at least one dose of mepolizumab. The observed discontinuation rate was 6/143 (4.2%). Five out of 6 discontinuations were due to lack of response, and one was an adverse event (urticaria) probably related to the treatment. There was no clinical difference between the drop-out group and the patients still ongoing. As compared to the clinical trials published the discontinuation rate was lower in our population, especially for adverse events (7% vs 23.7%). Thus, the tolerability of mepolizumab, as derived from discontinuations, seems to be better in real-life than in clinical trials.

KW - Mepolizumab

KW - Real-life: dropout

KW - Safety

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85059535018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059535018&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2018.12.003

DO - 10.1016/j.pupt.2018.12.003

M3 - Article

VL - 54

SP - 87

EP - 89

JO - Pulmonary Pharmacology and Therapeutics

T2 - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

ER -